<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00937703</url>
  </required_header>
  <id_info>
    <org_study_id>2008-A00270-55</org_study_id>
    <nct_id>NCT00937703</nct_id>
  </id_info>
  <brief_title>Multicentric Evaluation of Two Telematics Systems in Type 2 Diabetic Patients in Failure of Oral Treatment and Having to Start Treatment by Basal Insulin</brief_title>
  <acronym>TELEDIAB-2</acronym>
  <official_title>Multicentric Evaluation of Two Telematics Systems (PDA Phone and IVS)in Type 2 Diabetics Patients in Failure of Oral Treatment and Having to Start a Treatment by Basal Insulin, Compared to a Conventional Care. National, Multicentric, Comparative Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      TELEDIAB-2 is a national, multicenter, controlled, randomised trial. The primary objective of
      the study is to show that during the initiation of a basal insulin treatment , a computerized
      decision-making system of adaptation of the insulin, coupled to a distance follow-up (thanks
      to PDAphone or an interactive vocal server (IVS)), is able to improve metabolic control at
      the end of 4 mouths as compared with conventional care.

      Main judgment criteria: comparison of HbA1c means of the 2 groups profiting from a
      telemonitoring system compared to the reference group at 4 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Secondary objectives :

        1. - To compare the 2 methods of telemonitoring employed.

        2. - To evaluate the speed of the glycemic attack of the objective to the rising, according
           to the method of follow-up employed.

        3. - To evaluate the satisfaction of the patients and the doctors with respect to systems
           of telemonitoring, and improvement of the quality of life (DQOL).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison HbA1c means of the 2 groups profiting from a telemonitoring system compared to the reference group.</measure>
    <time_frame>To T4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of absolute HbA1c difference</measure>
    <time_frame>T0-T4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of evolution of HbA1c</measure>
    <time_frame>T0 and T4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of percentage of patients reaching HbA1c &lt; 7.0% in 4 months</measure>
    <time_frame>T0 and T4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of percentage of patients within the objective glycemic (the last 3 days Jeun Glycemia average with between 0.73 and 1.08 g/l) at the end of the study, and the average time allowing to achieve this goal</measure>
    <time_frame>T0 and T4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the average jeun glycemia the 14 days previous the visit in 4 months</measure>
    <time_frame>T4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the frequency of benign hypoglycemias, symptomatic or not, night and severe throughout study</measure>
    <time_frame>study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the evolution of the weight</measure>
    <time_frame>T0 and T4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of evolution of the quality of life at the beginning and at the end of the study (the scale of quality of life DHP as well as the items of dimension Satisfaction of the DQOL)</measure>
    <time_frame>T0 and T4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the time spent by physicians with patients during visit (either face to face visits or phone call visit);</measure>
    <time_frame>study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the satisfaction of the patients and physicians with the system and willingness to carry on the use of the system in routine care</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effective number of patients carrying on the use of the system in routine care, at their own expense and in agreement with their physician</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>TYPE 2 DIABETES</condition>
  <arm_group>
    <arm_group_label>Group1: Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>face to face visit à T4mounths</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group2: IVS Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>face to face visit at T4mounths plus telephone visits each 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group3: PDAphone group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PDA system face to face visit at T4mounths plus telephone visits each 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>paper support for glycaemia face to face visit at T4mounths</description>
    <arm_group_label>Group1: Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IVS</intervention_name>
    <description>patients transmit their glycaemia to the IVS, which advises them the insulin amount recommended by their physician in this situation.
Face to face visit at T4mounths plus telephone visits each 2 weeks.</description>
    <arm_group_label>Group2: IVS Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PDAphone</intervention_name>
    <description>Patients will receive PDA phone system. They will hace face to face visit at T4mounths and telephone visits each 2 weeks</description>
    <arm_group_label>Group3: PDAphone group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes since more than 3 years and claiming a strict balance glycemic;

          -  Patients treated since at least 3 months, by metformin and secreting insulinic (KNOWN
             or glinide);

          -  Patients uncontrolled with HbA1c ≥ 7.5% and &lt; 10% at the inclusion.

          -  BMI &lt; 40 ;

          -  Patients requiring a insulin treatment

          -  Patients agree to start a slow insulin treatment

          -  Patients already practising the glycemic self-monitoring or agree to learn it and
             practise it;

          -  Patients able to include/understand operation and to use the PDA-phone and/or the SVI;

          -  Patient not taking part in another biomedical research study

          -  Patients agree to carry out at least 2 finger sticks per day;

          -  More than 18 years, there is no higher age limit.

        Exclusion Criteria:

          -  Patients introducing any evolutionary pathology associated and not stabilized,
             exhibitor with an uncontrolled diabetes during the year to come;

          -  Patients in a situation which justifies of a clinical follow-up diabetologic more
             frequent than that (quarterly) envisaged by the study

          -  Patients requiring a transitory passage to insulin;

          -  Patients needing a hospitalization for the adaptation of insulin doses;

          -  Patients presenting a cardiologic event

          -  Patients presenting a hemoglobinopathy interfering with the proportioning of HbA1c;

          -  Patients suffering from drug-addiction, alcoholism or psychological troubles

          -  Type 1 or secondary diabetes

          -  Patients who don't need strict metabolic objectives;

          -  Pregnant or parturient patients

          -  person with no freedom.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillaume CHARPENTIER, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre Yves BENHAMOU, MD PHD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CH Aix en Provence</name>
      <address>
        <city>Aix en Provence</city>
        <zip>13100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal Alençon-Mamers</name>
      <address>
        <city>Alençon</city>
        <zip>61000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Avignon</name>
      <address>
        <city>Avignon</city>
        <zip>84000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Belfort Montbéliard</name>
      <address>
        <city>Belfort</city>
        <zip>90016</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Caen</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Gabriel Montpied</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH sud francilien</name>
      <address>
        <city>Corbeil Essonnes</city>
        <zip>91106</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Dreux</name>
      <address>
        <city>Dreux</city>
        <zip>28100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Pierre Zobda-Quitman</name>
      <address>
        <city>Fort de France</city>
        <zip>97261</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Bicêtre</name>
      <address>
        <city>Kremlin Bicêtre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH La Rochelle</name>
      <address>
        <city>La Rochelle</city>
        <zip>17000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Marseille-Hôpital Nord</name>
      <address>
        <city>Marseille</city>
        <zip>13000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Marseille Hôpitaux Sud</name>
      <address>
        <city>Marseille</city>
        <zip>13274</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de l'Agglomération Montargoise</name>
      <address>
        <city>Montagis</city>
        <zip>45207</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hôpital Jeanne d'Arc</name>
      <address>
        <city>Nancy</city>
        <zip>54201</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Nanterre</name>
      <address>
        <city>Nanterre</city>
        <zip>92000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nimes</name>
      <address>
        <city>Nimes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital COCHIN</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Haut Leveque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35056</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Saint Etienne</name>
      <address>
        <city>Saint Etienne</city>
        <zip>42023</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bégin</name>
      <address>
        <city>Saint Mandé</city>
        <zip>94160</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ch Valenciennes</name>
      <address>
        <city>Valenciennes</city>
        <zip>59322</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 10, 2009</study_first_submitted>
  <study_first_submitted_qc>July 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2009</study_first_posted>
  <last_update_submitted>December 12, 2013</last_update_submitted>
  <last_update_submitted_qc>December 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

